Jim Pearce

Jim Pearce is the Chief Investment Strategist of Personal Finance, our flagship publication, and manages two trading services, PF Pro and Mayhem Trader. He began his career as a stockbroker in 1983 and over the years has managed client investment portfolios for major banks, brokerage firms, and investment advisors. Jim earned a BA from The College of William & Mary and the CFP designation from the College of Financial Planning.

Analyst Articles

We added Kohl’s (KSS) to our portfolio on Jan. 11 when it dropped 20% after it reported weak December sales and reduced full-year earnings guidance. Since then it has traded flat, establishing strong support just below our entry level price. That is likely to remain the case through Feb. 23,… Read More

There may not be enough time to make it to our target price of $82 for Cardinal Health (CAH) when our target holding period for it expires on Feb. 22, but the quarterly earnings results the company released today gave it a strong shove in that direction, rising above… Read More

Somewhat surprisingly for a company that deals in lethal weapons, gun maker Sturm, Ruger & Co. (RGR) has been one of the tamest stocks in our portfolio. Since adding it on Nov. 15, its share price has deviated less than 5% in either direction. All that may change on Feb. 22, when the… Read More

Few recommendations have ignited as much “fan mail” as my addition of CVS to the portfolio two weeks ago. And with its next quarterly earnings report coming out later this week, I have a funny feeling there will be more on my way if the news is not good. But… Read More

GILD spent the first three weeks of January drifting lower until catching an updraft after Trump’s inauguration. That is somewhat ironic, since it is Trump who was viewed as the greatest threat to drug companies such as Gilead. Compounding matters for the healthcare sector is Trump’s disjointed approach to repealing… Read More